Today The Q2 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. Decreased by Northcoast Research (ZBH)

Today The Q2 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. Decreased by Northcoast Research (ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Northcoast Research cut their Q2 2017 earnings estimates for Zimmer Biomet Holdings in a report released on Friday. Northcoast Research analyst D. Keiser now expects that the firm will post earnings per share of $2.18 for the quarter, down from their previous forecast of $2.19. Northcoast Research has a “Neutral” rating on the stock. Northcoast Research also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.37 EPS.

Several other equities analysts have also recently issued reports on the company. Needham & Company LLC upgraded Zimmer Biomet Holdings from a “buy” rating to a “strong-buy” rating and decreased their price target for the company from $150.00 to $148.00 in a report on Tuesday, November 1st. Royal Bank Of Canada decreased their price target on Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating on the stock in a report on Tuesday, November 1st. J P Morgan Chase & Co set a $134.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Thursday, January 5th. Zacks Investment Research upgraded Zimmer Biomet Holdings from a “sell” rating to a “hold” rating in a report on Friday, December 16th. Finally, Citigroup Inc. upgraded Zimmer Biomet Holdings from a “sell” rating to a “neutral” rating in a report on Tuesday, November 29th. Four equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $130.45.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 114.56 on Monday. The stock has a 50 day moving average price of $107.15 and a 200-day moving average price of $117.96. Zimmer Biomet Holdings has a one year low of $88.27 and a one year high of $133.21. The firm has a market cap of $22.95 billion, a P/E ratio of 64.14 and a beta of 1.23.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.79. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.64 EPS.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its position in shares of Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the company’s stock valued at $125,000 after buying an additional 5 shares during the last quarter. IFP Advisors Inc raised its position in Zimmer Biomet Holdings by 0.5% in the second quarter. IFP Advisors Inc now owns 1,507 shares of the company’s stock worth $181,000 after buying an additional 8 shares in the last quarter. Cypress Wealth Advisors LLC raised its position in Zimmer Biomet Holdings by 0.4% in the second quarter. Cypress Wealth Advisors LLC now owns 3,081 shares of the company’s stock worth $371,000 after buying an additional 11 shares in the last quarter. Advisory Services Network LLC raised its position in Zimmer Biomet Holdings by 0.6% in the second quarter. Advisory Services Network LLC now owns 2,496 shares of the company’s stock worth $301,000 after buying an additional 15 shares in the last quarter. Finally, Capital One National Association raised its position in Zimmer Biomet Holdings by 0.3% in the third quarter. Capital One National Association now owns 5,670 shares of the company’s stock worth $738,000 after buying an additional 15 shares in the last quarter. Institutional investors and hedge funds own 85.86% of the company’s stock.

In related news, insider David A. Jr. Nolan sold 5,050 shares of the business’s stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $101.11, for a total value of $510,605.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.22% of the company’s stock.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.84%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 75.00%.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Related posts

Leave a Comment